<div id="readability-page-1"><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>Ab&amp;B Bio-Tech CO., LTD. JS Class H ( (HK:2627) ) has issued an update. Ab&amp;B Bio-Tech has initiated Phase I and Phase II clinical trials for its self-developed recombinant RSV vaccine using CHO cells with an adjuvant, following investigational new drug approval from China’s National Medical Products Administration. The candidate targets respiratory syncytial virus, a leading cause of acute respiratory infections in infants, the elderly and immunocompromised patients in China, where vaccination is seen as the preferred prevention strategy amid limited treatment options. Preclinical data suggest the vaccine achieves higher pre-F protein expression, improved thermal stability and stronger immunogenicity than marketed recombinant RSV vaccines, enabling a liquid formulation and showing a favorable safety profile in animal studies. Despite this pipeline progress, trading in the company’s H shares on the Hong Kong Stock Exchange remains suspended since April 1, 2026, and the company has cautioned investors that there is no assurance the RSV candidate will ultimately reach the market. More about Ab&amp;B Bio-Tech CO., LTD. JS Class H Ab&amp;B Bio-Tech CO., LTD. JS is a China-based vaccine developer focused on innovative and upgraded traditional vaccines targeting infectious diseases. The company’s pipeline includes quadrivalent and trivalent subunit influenza vaccines, a lyophilized human rabies vaccine candidate and other premium vaccine projects aimed at replacing traditional and imported products in China while expanding into international markets. Average Trading Volume: 1,068,891 Technical Sentiment Signal: Strong Sell Current Market Cap: HK$11.54B For a thorough assessment of 2627 stock, go to TipRanks’ Stock Analysis page.</div>

159892

516820

516500

Ab&B Bio-Tech CO., LTD. has begun Phase I and II trials for its recombinant RSV vaccine after receiving approval from China's National Medical Products Administration. The vaccine targets respiratory syncytial virus, crucial for vulnerable populations in China. Despite promising preclinical results, trading of the company's shares remains suspended since April 1, 2026, and there is no guarantee the vaccine will reach the market. Ab&B Bio-Tech focuses on innovative vaccines and has a diverse pipeline, including influenza and rabies vaccines.

Tip Ranks

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Ping An CSI Medicine and Medical Device Innovation ETF

ChinaAMC CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

Tianhong CNI BIOMEDICINE ETF

E Fund CSI Biotechnology Theme ETF

Bosera Hang Seng Health Care ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ICBCCS SSE STAR Biology and Medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Bosera Hang Seng SCHK Innovative Drug Select ETF

Penghua SSE STAR Biology and Medicine ETF

Huaan Hang Seng Biotech ETF

E Fund CSI 300 Health Care ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

China Southern Hang Seng Biotech ETF(QDII)

ChinaAMC SSE STAR Biology and Medicine ETF

AB&B BIO-TECH-B

Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended